PDB35 COST-UTILITY ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS HUMAN INSULIN IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN TIER III HOSPITALS IN BEIJING, CHINA- A LONGTERM OUTCOMES MODEL EVALUATION FROM THE IMPROVE OBSERVATIONAL STUDY
Nov 1, 2008, 00:00 AM
10.1016/S1098-3015(10)66683-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)66683-1/fulltext
Section Title :
Section Order :
520
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66683-1&doi=10.1016/S1098-3015(10)66683-1